BioVie Invites Investors to an Informative Webinar
CARSON CITY, Nev. — BioVie Inc. (NASDAQ: BIVI), a prominent clinical-stage company, is set to host a significant investor webinar that promises to shed light on its cutting-edge drug therapies for neurological and neurodegenerative diseases. The event is scheduled for 4:15 p.m. ET on a Wednesday this October.
Insightful Discussions Led by BioVie’s Leadership
Cuong Do, the president and CEO of BioVie, will lead the webinar, providing attendees with valuable insights into bezisterim (NE3107). This innovative, orally available small molecule targets two critical issues — inflammation and insulin resistance, which are key contributors to Alzheimer’s, Parkinson’s, and long COVID. Recent clinical studies have exhibited promising signs of enhanced cognitive abilities, improved motor functions, and diminished neuroinflammation.
Recent Advances in BioVie’s Clinical Trials
In addition to bezisterim, Do will discuss BIV201, BioVie’s late-stage orphan drug candidate aimed at treating refractory ascites, a severe complication related to liver cirrhosis. This presents a crucial development in a market that currently lacks FDA-approved solutions, marking a significant step forward for patients suffering from such debilitating conditions.
Commitment to Innovation and Future Milestones
With a pipeline rich in late-stage clinical programs and promising safety data, BioVie is progressing towards achieving key milestones. The company is actively exploring strategic partnerships that could leverage the extensive commercial potential of its therapies. This proactive approach positions BioVie favorably in an ever-evolving pharmaceutical landscape.
Interactive Q&A Session to Engage Attendees
To enhance the educational experience, the webinar will conclude with a live Q&A session where attendees can pose questions directly to BioVie’s management. This interactive component aims to facilitate a deeper understanding of the company’s vision and the significance of its innovative therapies.
How to Register for the Webinar
Investors interested in learning more about BioVie’s developments and strategies can register for this free webinar. Simply visit the company’s dedicated registration page to secure a spot in this informative session.
About BioVie, Inc.
BioVie Inc. (NASDAQ: BIVI) is committed to advancing medical science through the development of innovative drug therapies targeting neurological and neurodegenerative disorders. The company strategically focuses on conditions such as Alzheimer’s disease, Parkinson’s disease, long COVID, and advanced liver disease.
Research and Development Focus
BioVie aims to combat neuroinflammation and insulin resistance — both critical factors associated with Alzheimer’s and Parkinson’s diseases. Their drug candidate bezisterim is designed to inhibit inflammatory processes without affecting essential homeostatic functions. The company is also evaluating BIV201, a promising continuous infusion therapy for patients with cirrhosis and ascites, currently under the watchful gaze of the FDA.
Through innovation and a commitment to addressing unmet medical needs, BioVie is paving the way for advancements in treatment protocols. For further information about their research and ongoing projects, visit their official website.
Frequently Asked Questions
What is the focus of BioVie’s upcoming webinar?
The webinar will highlight BioVie’s innovative therapies for neurological and neurodegenerative diseases, featuring insights from its CEO.
How can I participate in the live Q&A session?
Attendees can submit their questions during the webinar, allowing for direct interaction with BioVie’s management team.
What is bezisterim?
Bezisterim (NE3107) is an orally available small molecule developed by BioVie, aimed at targeting inflammation and insulin resistance linked to various neurological conditions.
What is BIV201?
BIV201 is BioVie’s late-stage orphan drug candidate for treating refractory ascites associated with liver cirrhosis, designed to fill a critical gap in current treatment options.
How can I find more information about BioVie?
For further details regarding BioVie’s therapeutic developments and ongoing clinical trials, visit the company’s official website.
